Aiosyn’s AI-powered Mitosis Detection Solution is Now Accessible in Sectra Amplifier Marketplace

Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney diseases, has announced the integration of its innovative mitosis detection algorithm, Aiosyn Mitosis Breast*, with Sectra’s solution for digital pathology. It is now part of the Sectra Amplifier Marketplace. This allows pathology laboratories worldwide using Sectra’s solution to seamlessly incorporate Aiosyn Mitosis Breast into their existing workflow.

Aiosyn Mitosis Breast is a modular and flexible software offered as a service solution that can be integrated into existing digital pathology software and deployed through the cloud or on-premise installation. This product aids pathologists in tumor grading by identifying and highlighting mitotic figures in H&E sections before cases are opened for review, indicating areas with mitotic activity, and assisting in quantification. It offers invaluable support to pathologists tasked with the analysis of whole slide images from breast biopsies and resections. Aiosyn Mitosis Breast has proven to improve the efficiency and consistency of this tedious and subjective task in a multi-center clinical study conducted in collaboration with Radboud university medical center (publication pending).

“Integrating Aiosyn Mitosis Breast into the Sectra Amplifier Marketplace represents a unique opportunity for pathology labs to explore this advanced technology. As we await CE-IVDR certification for clinical use, we invite labs to join a non-clinical pilot program to experience the potential improvements in efficiency and consistency offered by our solution,” said David Tellez, CTO of Aiosyn.

The Sectra Amplifier Marketplace is a curated storefront showcasing AI applications and aims to accelerate the adoption of AI into clinical practice. By integrating Aiosyn Mitosis Breast in the Sectra workflow, pathology laboratories can leverage this AI-powered solution for efficient and consistent mitotic figure counting.

Following the integration of AiosynQC with Sectra’s digital pathology solution and the Paige AppLab platform, the integration of Aiosyn Mitosis Breast marks another significant milestone in Aiosyn’s mission to provide AI-powered pathology anywhere, anytime. Aiosyn remains committed to expanding its portfolio of deep learning algorithms and integrating them into imaging solutions, such as Sectra’s.

* Note: Aiosyn Mitosis Breast is currently designated for Research Use Only. It is in the process of obtaining CE-mark certification under the EU In Vitro Diagnostic Regulation (IVDR) for its application in clinical diagnostics.

About Aiosyn

Aiosyn is a Dutch company that develops precision pathology software for cancer and kidney disease. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon more than 20 years of research experience in the field of pathology and is rooted in pathology practice.


Anna Correas, Marketing & Communications Specialist at Aiosyn

Share This Post

Leave a Reply